AbL Diagnostics SA (ABLD) - Total Liabilities

Latest as of December 2025: €5.32 Million EUR ≈ $6.22 Million USD

Based on the latest financial reports, AbL Diagnostics SA (ABLD) has total liabilities worth €5.32 Million EUR (≈ $6.22 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

AbL Diagnostics SA - Total Liabilities Trend (2007–2025)

This chart illustrates how AbL Diagnostics SA's total liabilities have evolved over time, based on quarterly financial data. See ABLD working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

AbL Diagnostics SA Competitors by Total Liabilities

The table below lists competitors of AbL Diagnostics SA ranked by their total liabilities.

Company Country Total Liabilities
Lake Victoria Gold Ltd.
V:LVG
Canada CA$1.93 Million
Kaya Limited
NSE:KAYA
India Rs4.01 Billion
Globe Metals & Mining Ltd
AU:GBE
Australia AU$628.00K
TWL Holdings Bhd
KLSE:7079
Malaysia RM148.38 Million
Asia Plastic Recycling Holding Ltd
TW:1337
Taiwan NT$2.44 Billion
Routon Electronic Co Ltd
SHG:600355
China CN¥147.15 Million
Lien Chang Electronic Enterprise Co Ltd
TW:2431
Taiwan NT$171.19 Million
Samebest Co Ltd
TWO:8489
Taiwan NT$1.08 Billion

Liability Composition Analysis (2007–2025)

This chart breaks down AbL Diagnostics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ABLD market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.41 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.70 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.41 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how AbL Diagnostics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for AbL Diagnostics SA (2007–2025)

The table below shows the annual total liabilities of AbL Diagnostics SA from 2007 to 2025.

Year Total Liabilities Change
2025-12-31 €5.32 Million
≈ $6.22 Million
+23.11%
2024-12-31 €4.32 Million
≈ $5.05 Million
-46.86%
2023-12-31 €8.14 Million
≈ $9.51 Million
-5.99%
2022-12-31 €8.65 Million
≈ $10.12 Million
+9081.14%
2021-12-31 €94.26K
≈ $110.20K
+420.78%
2020-12-31 €18.10K
≈ $21.16K
-84.70%
2019-12-31 €118.31K
≈ $138.32K
-80.07%
2018-12-31 €593.64K
≈ $694.03K
+346.04%
2017-12-31 €133.09K
≈ $155.60K
-17.93%
2016-12-31 €162.18K
≈ $189.60K
-79.83%
2015-12-31 €804.11K
≈ $940.09K
+460.64%
2014-12-31 €143.43K
≈ $167.68K
-34.43%
2013-12-31 €218.75K
≈ $255.74K
+151.83%
2012-12-31 €86.86K
≈ $101.55K
-21.84%
2011-12-31 €111.14K
≈ $129.94K
+2.38%
2010-12-31 €108.56K
≈ $126.91K
+90.10%
2009-12-31 €57.10K
≈ $66.76K
+12.32%
2008-12-31 €50.84K
≈ $59.44K
-1.20%
2007-12-31 €51.46K
≈ $60.16K
--

About AbL Diagnostics SA

PA:ABLD France Health Information Services
Market Cap
$45.09 Million
€38.57 Million EUR
Market Cap Rank
#22640 Global
#357 in France
Share Price
€2.40
Change (1 day)
+0.00%
52-Week Range
€2.22 - €5.65
All Time High
€16.08
About

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more